Ligand Pharmaceuticals (LGND)
Ligand Pharmaceuticals Statistics
Share Statistics
Ligand Pharmaceuticals has 19.26M shares outstanding. The number of shares has increased by 7.19% in one year.
| Shares Outstanding | 19.26M |
| Shares Change (YoY) | 7.19% |
| Shares Change (QoQ) | 1.91% |
| Owned by Institutions (%) | 98.95% |
| Shares Floating | 18.78M |
| Failed to Deliver (FTD) Shares | 49 |
| FTD / Avg. Volume | 0.04% |
Short Selling Information
The latest short interest is 1.01M, so 5.34% of the outstanding shares have been sold short.
| Short Interest | 1.01M |
| Short % of Shares Out | 5.34% |
| Short % of Float | 7.38% |
| Short Ratio (days to cover) | 7.46 |
Valuation Ratios
The PE ratio is -486.05 and the forward PE ratio is 15.37. Ligand Pharmaceuticals's PEG ratio is 4.53.
| PE Ratio | -486.05 |
| Forward PE | 15.37 |
| PS Ratio | 11.73 |
| Forward PS | 5.9 |
| PB Ratio | 2.36 |
| P/FCF Ratio | 20.58 |
| PEG Ratio | 4.53 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Ligand Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.93, with a Debt / Equity ratio of 0.01.
| Current Ratio | 8.93 |
| Quick Ratio | 8.55 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | 0.17 |
| Debt / FCF | 0.07 |
| Interest Coverage | -7.44 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $2.46M |
| Profits Per Employee | $-59.29K |
| Employee Count | 68 |
| Asset Turnover | 0.18 |
| Inventory Turnover | 0.78 |
Taxes
| Income Tax | -6.55M |
| Effective Tax Rate | -260.13% |
Stock Price Statistics
The stock price has increased by 53.17% in the last 52 weeks. The beta is 0.97, so Ligand Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 0.97 |
| 52-Week Price Change | 53.17% |
| 50-Day Moving Average | 109.76 |
| 200-Day Moving Average | 109.13 |
| Relative Strength Index (RSI) | 53.03 |
| Average Volume (20 Days) | 114.15K |
Income Statement
In the last 12 months, Ligand Pharmaceuticals had revenue of 167.13M and earned -4.03M in profits. Earnings per share was -0.22.
| Revenue | 167.13M |
| Gross Profit | 156.06M |
| Operating Income | -22.61M |
| Net Income | -4.03M |
| EBITDA | 40.79M |
| EBIT | 5.55M |
| Earnings Per Share (EPS) | -0.22 |
Balance Sheet
The company has 72.31M in cash and 7.11M in debt, giving a net cash position of 65.2M.
| Cash & Cash Equivalents | 72.31M |
| Total Debt | 7.11M |
| Net Cash | 65.2M |
| Retained Earnings | 498.98M |
| Total Assets | 941.77M |
| Working Capital | 294.45M |
Cash Flow
In the last 12 months, operating cash flow was 97.05M and capital expenditures -1.82M, giving a free cash flow of 95.23M.
| Operating Cash Flow | 97.05M |
| Capital Expenditures | -1.82M |
| Free Cash Flow | 95.23M |
| FCF Per Share | 5.21 |
Margins
Gross margin is 93.37%, with operating and profit margins of -13.53% and -2.41%.
| Gross Margin | 93.37% |
| Operating Margin | -13.53% |
| Pretax Margin | 1.51% |
| Profit Margin | -2.41% |
| EBITDA Margin | 24.41% |
| EBIT Margin | -13.53% |
| FCF Margin | 56.98% |
Dividends & Yields
LGND does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for LGND is $143, which is 32.3% higher than the current price. The consensus rating is "Buy".
| Price Target | $143 |
| Price Target Difference | 32.3% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
Stock Splits
The last stock split was on Nov 2, 2022. It was a forward split with a ratio of 1603:1000.
| Last Split Date | Nov 2, 2022 |
| Split Type | forward |
| Split Ratio | 1603:1000 |
Scores
| Altman Z-Score | 11.16 |
| Piotroski F-Score | 3 |